Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) receives a Buy rating and $57.00 price target from H.C. Wainwright analyst. Promising results from ARROW trial for GAVRETO in treating RET fusion-positive NSCLC and solid tumors showcased safety, strong efficacy, and meaningful outcomes. Analyst sees optimistic market potential for the drug across various solid tumors.

Trial data supports GAVRETO’s anti-tumor activity in treating RET fusion-positive solid tumors, indicating positive market potential. Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) focuses on developing targeted drugs in oncology, immunology, and immune oncology. Product portfolio includes Tavalisse, Fostamatinib, and R835, portraying company’s commitment to innovative treatments.

Although RIGL shows investment potential, certain AI stocks offer higher upside potential with lower risk. For an undervalued AI stock benefiting from Trump-era tariffs and onshoring trend, check out the free report on the best short-term AI stock. Explore more stocks with potential to double in 3 years and hidden AI stocks to consider for investment opportunities.

Read more at Yahoo Finance: H.C. Wainwright Reiterates a Buy Rating on Rigel Pharmaceuticals (RIGL)